References
Abdulamir, A. S., Gorial, F. I., Saadi, S. J., Maulood, M. F., Hashim,
H. A., Alnuaimi, A. S., & Abdulrrazaq, M. K. (2021). A randomised
controlled trial of effectiveness and safety of Niclosamide as add on
therapy to the standard of care measures in COVID-19 management.Annals of medicine and surgery (2012), 69 , 102779-102779.
doi:10.1016/j.amsu.2021.102779
Al-Gareeb, A. I. A., Gorial, F. I., & Mahmood, A. S. (2018).
Niclosamide as an adjuvant to etanercept in treatment patients with
active rheumatoid arthritis: an 8-week randomized controlled pilot
study. Clin Rheumatol, 37 (10), 2633-2641.
doi:10.1007/s10067-018-4164-5
Al-Hadiya, B. M. (2005). Niclosamide: comprehensive profile.Profiles Drug Subst Excip Relat Methodol, 32 , 67-96.
doi:10.1016/s0099-5428(05)32002-8
Andrews, P., Thyssen, J., & Lorke, D. (1982). The biology and
toxicology of molluscicides, Bayluscide. Pharmacol Ther, 19 (2),
245-295. doi:10.1016/0163-7258(82)90064-x
Arend, R. C., Londoño-Joshi, A. I., Gangrade, A., Katre, A. A., Kurpad,
C., Li, Y., . . . Buchsbaum, D. J. (2016). Niclosamide and its analogs
are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in
ovarian cancer. Oncotarget, 7 (52), 86803-86815.
doi:10.18632/oncotarget.13466
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M.,
Hidalgo, B., . . . Buchsbaum, D. J. (2014). Inhibition of Wnt/β-catenin
pathway by niclosamide: a therapeutic target for ovarian cancer.Gynecol Oncol, 134 (1), 112-120. doi:10.1016/j.ygyno.2014.04.005
Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: identifying
and developing new uses for existing drugs. Nat Rev Drug Discov,
3 (8), 673-683. doi:10.1038/nrd1468
Backer, V., Sjöbring, U., Sonne, J., Weiss, A., Hostrup, M., Johansen,
H. K., . . . Sommer, M. O. A. (2021). A randomized, double-blind,
placebo-controlled phase 1 trial of inhaled and intranasal niclosamide:
A broad spectrum antiviral candidate for treatment of COVID-19.Lancet Reg Health Eur , 100084. doi:10.1016/j.lanepe.2021.100084
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B.
S., Kalil, A. C., . . . Lane, H. C. (2020). Remdesivir for the Treatment
of Covid-19 - Final Report. N Engl J Med, 383 (19), 1813-1826.
doi:10.1056/NEJMoa2007764
Beniac, D. R., Andonov, A., Grudeski, E., & Booth, T. F. (2006).
Architecture of the SARS coronavirus prefusion spike. Nat Struct
Mol Biol, 13 (8), 751-752. doi:10.1038/nsmb1123
Boyapally, R., Pulivendala, G., Bale, S., & Godugu, C. (2019).
Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by
attenuation of epithelial-to-mesenchymal transition, matrix proteins &
Wnt/β-catenin signaling: A drug repurposing study. Life Sci, 220 ,
8-20. doi:10.1016/j.lfs.2018.12.061
Braga, C. L., Felix, N. S., Teixeira, D. E., Vieira, J. B.,
Silva-Aguiar, R. P., Bose, R. M., . . . Silva, P. L. (2020). Niclosamide
attenuates lung vascular remodeling in experimental pulmonary arterial
hypertension. Eur J Pharmacol, 887 , 173438.
doi:10.1016/j.ejphar.2020.173438
Braga, L., Ali, H., Secco, I., Chiavacci, E., Neves, G., Goldhill, D., .
. . Giacca, M. (2021). Drugs that inhibit TMEM16 proteins block
SARS-CoV-2 Spike-induced syncytia. Nature .
doi:10.1038/s41586-021-03491-6
Breckenridge, A., & Jacob, R. (2019). Overcoming the legal and
regulatory barriers to drug repurposing. Nat Rev Drug Discov,
18 (1), 1-2. doi:10.1038/nrd.2018.92
Brunaugh, A. D., Seo, H., Warnken, Z., Ding, L., Seo, S. H., & Smyth,
H. D. C. (2021). Development and evaluation of inhalable composite
niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable
treatment for coronavirus infections and sequalae. PLoS One,
16 (2), e0246803. doi:10.1371/journal.pone.0246803
Cabrita, I., Benedetto, R., Schreiber, R., & Kunzelmann, K. (2019).
Niclosamide repurposed for the treatment of inflammatory airway disease.JCI Insight, 4 (15). doi:10.1172/jci.insight.128414
Centeio, R., Ousingsawat, J., Cabrita, I., Schreiber, R., Talbi, K.,
Benedetto, R., . . . Kunzelmann, K. (2021). Mucus Release and Airway
Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung
Disease. International journal of molecular sciences, 22 (15),
7852. doi:10.3390/ijms22157852
Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020). Virology,
transmission, and pathogenesis of SARS-CoV-2. Bmj, 371 , m3862.
doi:10.1136/bmj.m3862
Chen, B., Wei, W., Ma, L., Yang, B., Gill, R. M., Chua, M. S., . . . So,
S. (2017). Computational Discovery of Niclosamide Ethanolamine, a
Repurposed Drug Candidate That Reduces Growth of Hepatocellular
Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle
37 Signaling. Gastroenterology, 152 (8), 2022-2036.
doi:10.1053/j.gastro.2017.02.039
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., . . . Zhou,
J. (2013). Discovery of O-Alkylamino Tethered Niclosamide Derivatives as
Potent and Orally Bioavailable Anticancer Agents. ACS Med Chem
Lett, 4 (2), 180-185. doi:10.1021/ml3003082
Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome
structure, replication, and pathogenesis. J Med Virol, 92 (4),
418-423. doi:10.1002/jmv.25681
Cheng, B., Morales, L. D., Zhang, Y., Mito, S., & Tsin, A. (2017).
Niclosamide induces protein ubiquitination and inhibits multiple
pro-survival signaling pathways in the human glioblastoma U-87 MG cell
line. PLoS One, 12 (9), e0184324. doi:10.1371/journal.pone.0184324
Choi, H.-I., Kim, T., Lee, S.-W., Woo Kim, J., Ju Noh, Y., Kim, G.-Y., .
. . Koo, T.-S. (2021). Bioanalysis of niclosamide in plasma using liquid
chromatography-tandem mass and application to pharmacokinetics in rats
and dogs. Journal of Chromatography B, 1179 , 122862.
doi:https://doi.org/10.1016/j.jchromb.2021.122862
Fan, X., Xu, J., Files, M., Cirillo, J. D., Endsley, J. J., Zhou, J., &
Endsley, M. A. (2019). Dual activity of niclosamide to suppress
replication of integrated HIV-1 and Mycobacterium tuberculosis
(Beijing). Tuberculosis (Edinb), 116s , S28-s33.
doi:10.1016/j.tube.2019.04.008
Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their
replication and pathogenesis. Methods Mol Biol, 1282 , 1-23.
doi:10.1007/978-1-4939-2438-7_1
Fisk, M., Althage, M., Moosmang, S., Greasley, P. J., Cope, A. P.,
Jayne, D. R., . . . Cheriyan, J. (2021). Endothelin antagonism and
sodium glucose Co-transporter 2 inhibition. A potential combination
therapeutic strategy for COVID-19. Pulm Pharmacol Ther, 69 ,
102035. doi:10.1016/j.pupt.2021.102035
Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L., & Annunziato, F.
(2021). The central role of the nasal microenvironment in the
transmission, modulation, and clinical progression of SARS-CoV-2
infection. Mucosal Immunol, 14 (2), 305-316.
doi:10.1038/s41385-020-00359-2
Gao, H., Yao, H., Yang, S., & Li, L. (2016). From SARS to MERS:
evidence and speculation. Front Med, 10 (4), 377-382.
doi:10.1007/s11684-016-0466-7
Garrett, T. J., Coatsworth, H., Mahmud, I., Hamerly, T., Stephenson, C.
J., Yazd, H. S., . . . Dinglasan, R. R. (2021). Niclosamide reverses
SARS-CoV-2 control of lipophagy. bioRxiv , 2021.2007.2011.451951.
doi:10.1101/2021.07.11.451951
Gassen, N. C., Niemeyer, D., Muth, D., Corman, V. M., Martinelli, S.,
Gassen, A., . . . Rein, T. (2019). SKP2 attenuates autophagy through
Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus
infection. Nat Commun, 10 (1), 5770.
doi:10.1038/s41467-019-13659-4
Gassen, N. C., Papies, J., Bajaj, T., Emanuel, J., Dethloff, F., Chua,
R. L., . . . Müller, M. A. (2021). SARS-CoV-2-mediated dysregulation of
metabolism and autophagy uncovers host-targeting antivirals.Nature Communications, 12 (1), 3818.
doi:10.1038/s41467-021-24007-w
Gralinski, L. E., & Baric, R. S. (2015). Molecular pathology of
emerging coronavirus infections. J Pathol, 235 (2), 185-195.
doi:10.1002/path.4454
Gwisai, T., Hollingsworth, N. R., Cowles, S., Tharmalingam, N.,
Mylonakis, E., Fuchs, B. B., & Shukla, A. (2017). Repurposing
niclosamide as a versatile antimicrobial surface coating against
device-associated, hospital-acquired bacterial infections. Biomed
Mater, 12 (4), 045010. doi:10.1088/1748-605X/aa7105
Gyamfi, J., Lee, Y. H., Min, B. S., & Choi, J. (2019). Niclosamide
reverses adipocyte induced epithelial-mesenchymal transition in breast
cancer cells via suppression of the interleukin-6/STAT3 signalling axis.Sci Rep, 9 (1), 11336. doi:10.1038/s41598-019-47707-2
Hamdoun, S., Jung, P., & Efferth, T. (2017). Drug Repurposing of the
Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia.Front Pharmacol, 8 , 110. doi:10.3389/fphar.2017.00110
Han, Z., Li, Q., Wang, Y., Wang, L., Li, X., Ge, N., . . . Guo, C.
(2018). Niclosamide Induces Cell Cycle Arrest in G1 Phase in Head and
Neck Squamous Cell Carcinoma Through Let-7d/CDC34 Axis. Front
Pharmacol, 9 , 1544. doi:10.3389/fphar.2018.01544
Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L.,
Linsell, L., . . . Landray, M. J. (2021). Dexamethasone in Hospitalized
Patients with Covid-19. N Engl J Med, 384 (8), 693-704.
doi:10.1056/NEJMoa2021436
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal,
P. (2013). Computational drug repositioning: from data to therapeutics.Clin Pharmacol Ther, 93 (4), 335-341. doi:10.1038/clpt.2013.1
Imperi, F., Massai, F., Ramachandran Pillai, C., Longo, F., Zennaro, E.,
Rampioni, G., . . . Leoni, L. (2013). New life for an old drug: the
anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum
sensing. Antimicrob Agents Chemother, 57 (2), 996-1005.
doi:10.1128/aac.01952-12
Jin, Y., Lu, Z., Ding, K., Li, J., Du, X., Chen, C., . . . Pan, J.
(2010). Antineoplastic mechanisms of niclosamide in acute myelogenous
leukemia stem cells: inactivation of the NF-kappaB pathway and
generation of reactive oxygen species. Cancer Res, 70 (6),
2516-2527. doi:10.1158/0008-5472.Can-09-3950
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., . . . Yang, H.
(2020). Structure of M(pro) from SARS-CoV-2 and discovery of its
inhibitors. Nature, 582 (7811), 289-293.
doi:10.1038/s41586-020-2223-y
Jung, E., Nam, S., Oh, H., Jun, S., Ro, H.-J., Kim, B., . . . Go, Y. Y.
(2019). Neutralization of Acidic Intracellular Vesicles by Niclosamide
Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro.Scientific Reports, 9 (1), 8682. doi:10.1038/s41598-019-45095-1
Jurgeit, A., McDowell, R., Moese, S., Meldrum, E., Schwendener, R., &
Greber, U. F. (2012). Niclosamide is a proton carrier and targets acidic
endosomes with broad antiviral effects. PLoS Pathog, 8 (10),
e1002976. doi:10.1371/journal.ppat.1002976
Jurgeit, A., Moese, S., Roulin, P., Dorsch, A., Lötzerich, M., Lee, W.
M., & Greber, U. F. (2010). An RNA replication-center assay for high
content image-based quantifications of human rhinovirus and
coxsackievirus infections. Virol J, 7 , 264.
doi:10.1186/1743-422x-7-264
Kao, J. C., HuangFu, W. C., Tsai, T. T., Ho, M. R., Jhan, M. K., Shen,
T. J., . . . Lin, C. F. (2018). The antiparasitic drug niclosamide
inhibits dengue virus infection by interfering with endosomal
acidification independent of mTOR. PLoS Negl Trop Dis, 12 (8),
e0006715. doi:10.1371/journal.pntd.0006715
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch,
M. (2020). Projecting the transmission dynamics of SARS-CoV-2 through
the postpandemic period. Science, 368 (6493), 860-868.
doi:10.1126/science.abb5793
Li, R., You, S., Hu, Z., Chen, Z. G., Sica, G. L., Khuri, F. R., . . .
Deng, X. (2013). Inhibition of STAT3 by niclosamide synergizes with
erlotinib against head and neck cancer. PLoS One, 8 (9), e74670.
doi:10.1371/journal.pone.0074670
Li, X., Yang, Z., Han, Z., Wen, Y., Ma, Z., & Wang, Y. (2018).
Niclosamide acts as a new inhibitor of vasculogenic mimicry in oral
cancer through upregulation of miR-124 and downregulation of STAT3.Oncol Rep, 39 (2), 827-833. doi:10.3892/or.2017.6146
Li, Z., Brecher, M., Deng, Y.-Q., Zhang, J., Sakamuru, S., Liu, B., . .
. Li, H. (2017). Existing drugs as broad-spectrum and potent inhibitors
for Zika virus by targeting NS2B-NS3 interaction. Cell Research,
27 (8), 1046-1064. doi:10.1038/cr.2017.88
Li, Z., Brecher, M., Deng, Y. Q., Zhang, J., Sakamuru, S., Liu, B., . .
. Li, H. (2017). Existing drugs as broad-spectrum and potent inhibitors
for Zika virus by targeting NS2B-NS3 interaction. Cell Res,
27 (8), 1046-1064. doi:10.1038/cr.2017.88
Liu, C., Armstrong, C. M., Lou, W., Lombard, A. P., Cucchiara, V., Gu,
X., . . . Gao, A. C. (2017). Niclosamide and Bicalutamide Combination
Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate
Cancer. Mol Cancer Ther, 16 (8), 1521-1530.
doi:10.1158/1535-7163.Mct-16-0912
Liu, C., Lou, W., Armstrong, C., Zhu, Y., Evans, C. P., & Gao, A. C.
(2015). Niclosamide suppresses cell migration and invasion in
enzalutamide resistant prostate cancer cells via Stat3-AR axis
inhibition. Prostate, 75 (13), 1341-1353. doi:10.1002/pros.23015
Lu, I. N., Kulkarni, S., Fisk, M., Kostapanos, M., Banham-Hall, E.,
Kadyan, S., . . . Cheriyan, J. (2020). muLTi-Arm Therapeutic study in
pre-ICu patients admitted with Covid-19-Experimental drugs and
mechanisms (TACTIC-E): A structured summary of a study protocol for a
randomized controlled trial. Trials, 21 (1), 690.
doi:10.1186/s13063-020-04618-2
Luo, F., Luo, M., Rong, Q. X., Zhang, H., Chen, Z., Wang, F., . . . Fu,
L. W. (2019). Niclosamide, an antihelmintic drug, enhances efficacy of
PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.J Immunother Cancer, 7 (1), 245. doi:10.1186/s40425-019-0733-7
Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley,
A. N., Green, C. E., . . . Tanga, M. J. (2015). Evaluation of Ebola
Virus Inhibitors for Drug Repurposing. ACS Infect Dis, 1 (7),
317-326. doi:10.1021/acsinfecdis.5b00030
Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley,
A. N., Green, C. E., . . . Tanga, M. J. (2015). Evaluation of Ebola
Virus Inhibitors for Drug Repurposing. ACS Infectious Diseases,
1 (7), 317-326. doi:10.1021/acsinfecdis.5b00030
Mazzon, M., Ortega-Prieto, A. M., Imrie, D., Luft, C., Hess, L., Czieso,
S., . . . Marsh, M. (2019). Identification of Broad-Spectrum Antiviral
Compounds by Targeting Viral Entry. Viruses, 11 (2).
doi:10.3390/v11020176
Miller, I. F., Becker, A. D., Grenfell, B. T., & Metcalf, C. J. E.
(2020). Disease and healthcare burden of COVID-19 in the United States.Nat Med, 26 (8), 1212-1217. doi:10.1038/s41591-020-0952-y
Miner, K., Labitzke, K., Liu, B., Wang, P., Henckels, K., Gaida, K., . .
. Sullivan, J. K. (2019). Drug Repurposing: The Anthelmintics
Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully
Bronchodilate Airways. Front Pharmacol, 10 , 51.
doi:10.3389/fphar.2019.00051
Mohammad, H., AbdelKhalek, A., Abutaleb, N. S., & Seleem, M. N. (2018).
Repurposing niclosamide for intestinal decolonization of
vancomycin-resistant enterococci. Int J Antimicrob Agents, 51 (6),
897-904. doi:10.1016/j.ijantimicag.2018.02.003
Monin, M. B., Krause, P., Stelling, R., Bocuk, D., Niebert, S., Klemm,
F., . . . Koenig, S. (2016). The anthelmintic niclosamide inhibits
colorectal cancer cell lines via modulation of the canonical and
noncanonical Wnt signaling pathway. J Surg Res, 203 (1), 193-205.
doi:10.1016/j.jss.2016.03.051
Nosengo, N. (2016). Can you teach old drugs new tricks? Nature,
534 (7607), 314-316. doi:10.1038/534314a
Parikh, M., Liu, C., Wu, C. Y., Evans, C. P., Dall’Era, M., Robles, D.,
. . . Pan, C. X. (2021). Phase Ib trial of reformulated niclosamide with
abiraterone/prednisone in men with castration-resistant prostate cancer.Sci Rep, 11 (1), 6377. doi:10.1038/s41598-021-85969-x
Paules, C. I., Marston, H. D., & Fauci, A. S. (2020). Coronavirus
Infections-More Than Just the Common Cold. Jama, 323 (8), 707-708.
doi:10.1001/jama.2020.0757
Pearson, R. D., & Hewlett, E. L. (1985). Niclosamide therapy for
tapeworm infections. Ann Intern Med, 102 (4), 550-551.
doi:10.7326/0003-4819-102-4-550
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S.,
Wells, A., . . . Pirmohamed, M. (2019). Drug repurposing: progress,
challenges and recommendations. Nat Rev Drug Discov, 18 (1),
41-58. doi:10.1038/nrd.2018.168
Rajamuthiah, R., Fuchs, B. B., Conery, A. L., Kim, W., Jayamani, E.,
Kwon, B., . . . Mylonakis, E. (2015). Repurposing salicylanilide
anthelmintic drugs to combat drug resistant Staphylococcus aureus.PLoS One, 10 (4), e0124595. doi:10.1371/journal.pone.0124595
Rochwerg, B., Siemieniuk, R. A., Agoritsas, T., Lamontagne, F., Askie,
L., Lytvyn, L., . . . Vandvik, P. O. (2020). A living WHO guideline on
drugs for covid-19. Bmj, 370 , m3379. doi:10.1136/bmj.m3379
Schweizer, M. T., Haugk, K., McKiernan, J. S., Gulati, R., Cheng, H. H.,
Maes, J. L., . . . Yu, E. Y. (2018). Correction: A phase I study of
niclosamide in combination with enzalutamide in men with
castration-resistant prostate cancer. PLoS One, 13 (8), e0202709.
doi:10.1371/journal.pone.0202709
Shangguan, F., Liu, Y., Ma, L., Qu, G., Lv, Q., An, J., . . . Cao, Q.
(2020). Niclosamide inhibits ovarian carcinoma growth by interrupting
cellular bioenergetics. J Cancer, 11 (12), 3454-3466.
doi:10.7150/jca.41418
Stewart, R. L., Carpenter, B. L., West, D. S., Knifley, T., Liu, L.,
Wang, C., . . . Chen, M. (2016). S100A4 drives non-small cell lung
cancer invasion, associates with poor prognosis, and is effectively
targeted by the FDA-approved anti-helminthic agent niclosamide.Oncotarget, 7 (23), 34630-34642. doi:10.18632/oncotarget.8969
Suliman, M. A., Zhang, Z., Na, H., Ribeiro, A. L., Zhang, Y., Niang, B.,
. . . Zuo, Y. (2016). Niclosamide inhibits colon cancer progression
through downregulation of the Notch pathway and upregulation of the
tumor suppressor miR-200 family. Int J Mol Med, 38 (3), 776-784.
doi:10.3892/ijmm.2016.2689
Sun, Z., & Zhang, Y. (1999). Antituberculosis activity of certain
antifungal and antihelmintic drugs. Tuber Lung Dis, 79 (5),
319-320. doi:10.1054/tuld.1999.0212
Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova,
M., . . . Barnes, J. L. (2020). SARS-CoV-2 entry factors are highly
expressed in nasal epithelial cells together with innate immune genes.Nat Med, 26 (5), 681-687. doi:10.1038/s41591-020-0868-6
TACTIC-E Trial. (2020). Retrieved from
https://cctu.org.uk/portfolio/COVID-19/TACTIC/TACTIC-E
Tam, J., Hamza, T., Ma, B., Chen, K., Beilhartz, G. L., Ravel, J., . . .
Melnyk, R. A. (2018). Host-targeted niclosamide inhibits C. difficile
virulence and prevents disease in mice without disrupting the gut
microbiota. Nat Commun, 9 (1), 5233.
doi:10.1038/s41467-018-07705-w
Tao, H., Zhang, Y., Zeng, X., Shulman, G. I., & Jin, S. (2014).
Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves
diabetic symptoms in mice. Nat Med, 20 (11), 1263-1269.
doi:10.1038/nm.3699
Tharmalingam, N., Port, J., Castillo, D., & Mylonakis, E. (2018).
Repurposing the anthelmintic drug niclosamide to combat Helicobacter
pylori. Sci Rep, 8 (1), 3701. doi:10.1038/s41598-018-22037-x
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S.,
& Ishige, N. (2015). Niclosamide suppresses migration of hepatocellular
carcinoma cells and downregulates matrix metalloproteinase-9 expression.Oncology letters, 10 (6), 3515-3518. doi:10.3892/ol.2015.3789
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S.,
Sueishi, M., & Yoshida, T. (2013). Niclosamide suppresses Hepatoma cell
proliferation via the Wnt pathway. OncoTargets and therapy, 6 ,
1685-1693. doi:10.2147/ott.s50065. (Accession No. 24273411)
Torres, N. S., Abercrombie, J. J., Srinivasan, A., Lopez-Ribot, J. L.,
Ramasubramanian, A. K., & Leung, K. P. (2016). Screening a Commercial
Library of Pharmacologically Active Small Molecules against
Staphylococcus aureus Biofilms. Antimicrob Agents Chemother,
60 (10), 5663-5672. doi:10.1128/aac.00377-16
Wang, C., Zhou, X., Xu, H., Shi, X., Zhao, J., Yang, M., . . . Liao, M.
(2018). Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity
of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway. J
Cancer, 9 (22), 4150-4155. doi:10.7150/jca.26948
Wang, J., Ren, X. R., Piao, H., Zhao, S., Osada, T., Premont, R. T., . .
. Chen, W. (2019). Niclosamide-induced Wnt signaling inhibition in
colorectal cancer is mediated by autophagy. Biochem J, 476 (3),
535-546. doi:10.1042/bcj20180385
Wang, L. H., Xu, M., Fu, L. Q., Chen, X. Y., & Yang, F. (2018). The
Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular
Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear
β-catenin/c-Myc axis in OSCC. Sci Rep, 8 (1), 12776.
doi:10.1038/s41598-018-30692-3
Weinbach, E. C., & Garbus, J. (1969). Mechanism of action of reagents
that uncouple oxidative phosphorylation. Nature, 221 (5185),
1016-1018. doi:10.1038/2211016a0
Weiss, A., Touret, F., Baronti, C., Gilles, M., Hoen, B., Nougairède,
A., . . . Sommer, M. O. A. (2021). Niclosamide shows strong antiviral
activity in a human airway model of SARS-CoV-2 infection and a conserved
potency against the UK B.1.1.7 and SA B.1.351 variant. bioRxiv ,
2021.2004.2026.441457. doi:10.1101/2021.04.26.441457
Wen, C. C., Kuo, Y. H., Jan, J. T., Liang, P. H., Wang, S. Y., Liu, H.
G., . . . Yang, N. S. (2007). Specific plant terpenoids and lignoids
possess potent antiviral activities against severe acute respiratory
syndrome coronavirus. J Med Chem, 50 (17), 4087-4095.
doi:10.1021/jm070295s
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller,
M., . . . Scheffler, B. (2013). Anticancer effects of niclosamide in
human glioblastoma. Clin Cancer Res, 19 (15), 4124-4136.
doi:10.1158/1078-0432.Ccr-12-2895
Wu, C. J., Jan, J. T., Chen, C. M., Hsieh, H. P., Hwang, D. R., Liu, H.
W., . . . Hsu, J. T. (2004). Inhibition of severe acute respiratory
syndrome coronavirus replication by niclosamide. Antimicrob Agents
Chemother, 48 (7), 2693-2696. doi:10.1128/aac.48.7.2693-2696.2004
Wu, M. M., Zhang, Z., Tong, C. W. S., Yan, V. W., Cho, W. C. S., & To,
K. K. W. (2020). Repurposing of niclosamide as a STAT3 inhibitor to
enhance the anticancer effect of chemotherapeutic drugs in treating
colorectal cancer. Life Sci, 262 , 118522.
doi:10.1016/j.lfs.2020.118522
Yang, C. W., Peng, T. T., Hsu, H. Y., Lee, Y. Z., Wu, S. H., Lin, W. H.,
. . . Lee, S. J. (2020). Repurposing old drugs as antiviral agents for
coronaviruses. Biomed J, 43 (4), 368-374.
doi:10.1016/j.bj.2020.05.003
Ye, T., Xiong, Y., Yan, Y., Xia, Y., Song, X., Liu, L., . . . Yu, L.
(2014). The anthelmintic drug niclosamide induces apoptosis, impairs
metastasis and reduces immunosuppressive cells in breast cancer model.PLoS One, 9 (1), e85887. doi:10.1371/journal.pone.0085887
Zeyada, M. S., Abdel-Rahman, N., El-Karef, A., Yahia, S., El-Sherbiny,
I. M., & Eissa, L. A. (2020). Niclosamide-loaded polymeric micelles
ameliorate hepatocellular carcinoma in vivo through targeting Wnt and
Notch pathways. Life Sci, 261 , 118458.
doi:10.1016/j.lfs.2020.118458
Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., . . .
Shi, Z. L. (2020). A pneumonia outbreak associated with a new
coronavirus of probable bat origin. Nature, 579 (7798), 270-273.
doi:10.1038/s41586-020-2012-7
Zuo, Y., Yang, D., Yu, Y., Xiang, M., Li, H., Yang, J., . . . Yu, Z.
(2018). Niclosamide enhances the cytotoxic effect of cisplatin in
cisplatin-resistant human lung cancer cells via suppression of lung
resistance-related protein and c-myc. Mol Med Rep, 17 (3),
3497-3502. doi:10.3892/mmr.2017.8301